Belimumab (Benlysta®) recommended as an option for restricted use within NHS Wales for active, autoantibody-positive systemic lupus erythematosus

Belimumab is restricted for the treatment of patients who have serological disease activity and SELENA-SLEDAI score ≥10 despite standard treatment. Treatment should be continued beyond 24 weeks only if the score has improved by ≥ 4 points.


All Wales Medicines Strategy Group